News

New Digital Cognitive Assessment Tool Receives Positive FDA Review

The cognitive science company Cogstate received approval to market a new digital cognitive assessment tool to assist healthcare professionals in measuring cognition in patients ages 6 to 99, either in-clinic or at home. This tool, called the Cognigram, could help measure the progression of Parkinson’s disease and other illnesses. The Cognigram can…

Prexton Therapeutics Initiates Phase 2 Trial of Foliglurax for Parkinson’s Patients

Prexton Therapeutics has initiated a new Phase 2 clinical trial to assess the safety and effectiveness of its investigational therapy Foliglurax (PXT002331) in Parkinson’s disease patients treated with levodopa, but who are experiencing end-of-dose wearing off and levodopa-induced dyskinesia (involuntary movements). Levodopa is the most important first-line medication for the management of Parkinson’s,…

Intec Pharma Granted Hong Kong Patent for Carbidopa/Levodopa Pill for Parkinson’s

Hong Kong has issued a patent to Intec Pharma for its investigational Accordion Pill Carbidopa/Levodopa (AP-CD/LD) drug delivery for Parkinson’s disease symptoms in advanced patients. The patent (HK1158545) is titled “Carbidopa/Levodopa Gastroretentive Drug Delivery” and is scheduled to remain active until April 2029. The patent belongs to Intec’s IN-7 patent family that…

Prana and Takeda Will Investigate PBT434 as Treatment for Gastrointestinal Damage in Parkinson’s

Prana Biotechnology and Takeda Pharmaceuticals International are teaming up to investigate whether Prana’s PBT434 can improve gastrointestinal damage associated with Parkinson’s disease. PBT434 showed promise as a treatment for neuronal loss and movement problems in mice with Parkinson’s, according to a preclinical-trial study. The collaboration will deal with…

Promo for the Parkinson's psychosis guide